[Toxicity and efficacy of chemotherapy dependent on circadian time of cytostatic drug administration]. / Toksycznosc i skutecznosc chemioterapii w zaleznosci od pory dnia podawania cytostatyków.

A prospective, controlled study was carried out in order to evaluate efficacy and toxicity of chemotherapy based on cisplatin in dependence on the circadian rhythm of drugs administration in patients with testicular and ovarian cancer. The study included 80 patients (40 with testicular cancer and 40 with ovarian cancer), divided into two groups (A and B). The cytostatics were administered in the evening in the group A and in the morning in the group B. The response rates and the 3-years survival rates were comparable in both groups. However the patients in the group A presented less haematological and renal side effects, while nausea and vomiting were milder. Chronotherapy may appear to be a method improving the tolerance of chemotherapy based on cisplatin.

[Late hematologic status after chemotherapy observed in patients 3 to 10 years after treatment]. / Pózne powiklania hematologiczne po leczeniu chemicznym obserwowane u pacjentów w 3 do 10 lat po leczeniu.

The aim of the present study is the evaluation of late hematological complication in patients who received aggressive chemotherapy, and were observed 3, 5 and 10 years after treatment was completed. In the group of 35 patients, besides high percent of early hematological complications, there was only one case of anemia grade 2 (acc. to WHO score). We concluded that the hematological recovery after aggressive chemotherapy was satisfactory. No secondary hematological malignancies have been found.

[Results of adjuvant therapy with the preparation Poly-a Poly-u in patients with malignant melanoma during a 10-year observation]. / Wyniki adjuwantnej terapii preparatem Poly-A Poly-U u chorych na czerniaka zlosliwego w 10-letniej obserwacji.

During 10 years patients with malignant melanoma were followed up after radical removal of primary tumour and metastatic regional lymph nodes, the half of whom was given immunomodulation with the preparation Poly-A Poly-U in a controlled clinical trial. It was found that the performed immunomodulation exerted slight effect on the course of malignant melanoma causing later development of recurrence, less dynamic course of the disease, longer asymptomatic periods in relation to the control group. No effect of the drug administration was observed on longterm survival.

[A rare case of dissemination of anaplastic oligodendroma outside the central nervous system]. / Rzadki przypadek rozsiewu anaplastycznego skapodrzewiaka poza osrodkowy uklad nerwowy.

A rare case is reported of primary brain tumour with histological features of anaplastic oligodendroglioma, with metastases outside the central nervous system. Of interest is a short remission after treatment with cyclophosphamide and vepesid which shows that this type of tumour is sensitive in a way to chemotherapy.

[Role of chemotherapy in the treatment of anaplastic thyroid cancer --personal observations]. / Rola chemioterapii w leczeniu anaplastycznego raka tarczycy--doswiadczenia wlasne.

Results of chemotherapy applied in 23 patients with anaplastic thyroid cancer are presented. Chemotherapy combined with local treatment is a suggested therapy for treatment the locally advanced anaplastic thyroid cancer.

[Assessment of causes for delayed treatment in patients with malignant neoplasms ]. / Ocena przyczyn opóznionego leczenia chorych na nowotwory zlosliwe.

Investigation of the causes of delay in the treatment of patients with malignant neoplasms indicates that medium time of delay caused by patient has been 7 months, and caused by physician 9 months. Investigations indicate also that time of waiting for admission to the Oncology Center has been averaging 3 weeks. It has been found that every 9-th patient has been under non medical care for average period of 7 months.

An attempt at applying epiadriamycin to the patients for whom doxorubicin is cardiologically contraindicated.

Administrating Epi-ADR (Epiadriamycin) to the patients for whom ADR was cardiologically contraindicated did not cause significant complications. No complications occurred in the patients treated with Epiadriamycin, after they had completed a full course of maximal dose of ADR. The trial was conducted in close cooperation with a cardiological intensive care unit which is an essential arrangement in such clinical situation, until the optimal therapeutical method of administrating Epi-ADR is defined with special attention devoted to its critical dose.